Combination of Artificial Intelligence and Mucosal Exposure Device to Enhance Colorectal Neoplasia Detection
Launched by CHINESE UNIVERSITY OF HONG KONG · Jun 8, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to improve the detection of colorectal issues, specifically adenomas (which are benign growths that can lead to cancer) and colorectal cancer. Researchers believe that using a combination of a special artificial intelligence system (called ENDOAID) and a device that helps expose the inner lining of the colon (called Endocuff Vision®) will be more effective at finding these problems compared to using the AI system alone. This trial is currently looking for participants aged 45 to 85 who need a colonoscopy for reasons like cancer screening or checking for symptoms like changes in bowel habits.
If you join the study, you can expect to undergo a colonoscopy using this combined approach. Before participating, you'll need to provide written consent and meet specific criteria, such as not having serious health conditions that could complicate the procedure. The trial is open to all genders, and the goal is to see if this new method can help doctors find colorectal issues more effectively, ultimately leading to better patient outcomes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Aged 45-85 years old;
- • 2. They require elective colonoscopy for colorectal cancer screening, polyp surveillance, or investigation of symptoms such as anemia or altered bowel habit;
- • 3. Written informed consent obtained.
- Exclusion Criteria:
- • 1. Contraindication to colonoscopy (e.g. intestinal obstruction or perforation)
- • 2. Contraindication or conditions precluding polyp resection (e.g. active gastrointestinal bleeding, uninterrupted anticoagulation or dual antiplatelets)
- • 3. Staged procedure for polypectomy or biopsy of known unresected lesions
- • 4. Previous surgical resection of colon
- • 5. Personal history of colorectal cancer
- • 6. Personal history of familial polyposis syndrome
- • 7. Personal history of inflammatory bowel disease
- • 8. Advanced comorbid conditions (defined as American Society of Anesthesiologists grade 4 or above)
- • 9. Pregnancy
- • 10. Unable to obtain informed consent
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shatin, Hong Kong Island, Hong Kong
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials